Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

COVID tests well tolerated by WA school kids

A study conducted across 40 WA schools has found COVID-19 testing using a combined nose and throat swab was well tolerated by children as young as 4 years.

News & Events

Minderoo Foundation funds vaccine trial to protect WA healthcare workers from COVID-19

At least 2,000 WA healthcare workers will help test whether an existing tuberculosis vaccine can reduce their chance of COVID-19 infection, lessen the severity of symptoms and boost immunity.

News & Events

Community advocate jumps on board with new COVID-19 advisory group

Like many of us, consumer and community advocate Catherine Hughes is worried about the impact of COVID-19. So she joined Australia’s first COVID-19 consumer reference group to be a voice for the community.

News & Events

Rapidly assembled advisory group to offer community take on COVID-19 research

The speed with which research projects on the coronavirus have been put together has consumer advocates concerned that a vital voice will be missing – that of the community.

Aboriginal and Torres Strait Islander resources

A number of organisations have created COVID-19 resources specifically developed for Aboriginal and Torres Strait Islander people.

Research

Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19

Because of its beneficial off-target effects against non-mycobacterial infectious diseases, bacillus Calmette-Guérin vaccination might be an accessible early intervention to boost protection against novel pathogens. Multiple epidemiological studies and randomised controlled trials are investigating the protective effect of BCG against coronavirus disease 2019 (COVID-19).

Research

Global Disparities of Cancer and Its Projected Burden in 2050

Cancer prevention and care efforts have been challenged by the COVID-19 pandemic and armed conflicts, resulting in a decline in the global Human Development Index (HDI), particularly in low- and middle-income countries. These challenges and subsequent shifts in health care priorities underscore the need to continuously monitor cancer outcome disparities and statistics globally to ensure delivery of equitable and optimal cancer prevention and care in uncertain times.

Research

Opportunities to strengthen respiratory virus surveillance systems in Australia: lessons learned from the COVID-19 response

Disease surveillance data was critical in supporting public health decisions throughout the coronavirus disease 2019 (COVID-19) pandemic. At the same time, the unprecedented circumstances of the pandemic revealed many shortcomings of surveillance systems for viral respiratory pathogens. Strengthening of surveillance systems was identified as a priority for the recently established Australian Centre for Disease Control, which represents a critical opportunity to review pre-pandemic and pandemic surveillance practices, and to decide on future priorities, during both pandemic and inter-pandemic periods.

Research

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response

SARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.

Research

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines

Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. The aim of this study was to validate whether immunogenicity differs for adenoviral vectored (AdV) versus mRNA vaccines against SARS-CoV-2, and to investigate how anti-vector immunity and B cell dynamics modulate immunogenicity.